Trial reportSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.
Trial report in Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens forBMJ open gastroenterology · 2026Pooled it
- High-Dose Dual Therapy Versus Bismuth-Containing Quadruple Therapy for the Treatment of Helicobacter pylori Infection: A Systematic Review with Meta-Analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Pooled it
- Pooled it
- Different dose of new generation proton pump inhibitors for the treatment ofInternational journal of immunopathology and pharmacologyPooled it
- High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment ofSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- Comparison of the Efficacy of 12-day Concomitant Quadruple Therapy versus 14-day High dose Dual Therapy as a First-lineThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Trial
- Evolution of Amoxicillin-Based Mono-Antibiotic Regimens forMicroorganisms · 2026Review
- Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan forMicroorganisms · 2025Review
- High-dose amoxicillin and pantoprazole regimen forPrzeglad gastroenterologiczny · 2025Article
- 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy forFrontiers in pharmacology · 2023Article
- High-dose dual therapyTherapeutic advances in gastroenterology · 2023Article
- Comparative effectiveness of first-line therapies for eradication of antibiotic-resistantWorld journal of clinical cases · 2022Article
- Efficacy of 14-day concomitant quadruple therapy and 14-day high-dose dual therapy onGastroenterology and hepatology from bed to bench · 2022Article
- Gastric histopathological features after the administration of omeprazole, amoxicillin, and clarithromycin in gastritisJournal of advanced veterinary and animal research · 2021Article
- High dose PPI-amoxicillin dual therapy for the treatment ofTherapeutic advances in gastroenterology · 2020Review
- Optimizing proton pump inhibitors inWorld journal of gastroenterology · 2019Review
- Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
- High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment ofTzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background\Aim: Quadruple daily administration of proton-pump inhibitor (PPI) therapy achieves potent acid inhibition, and combined with amoxicillin, with its pharmacodynamic and pharmacokinetic characteristics, may be efficient for Helicobacter pylori eradication. We compared the efficacy of two optimized high-dose dual therapies with a bismuth-containing quadruple regimen for treating H. pylori infection. Rabeprazole dosages for H. pylori eradication were also evaluated. PATIENTS AND
methodsTreatment-naive and H. pylori-positive subjects were recruited and randomly apportioned to three treatment groups: Group A (n = 87), rabeprazole 10 mg plus amoxicillin 750 mg (4 times/day for 14 days); Group B (n = 87), rabeprazole 20 mg plus amoxicillin 750 mg (4 times/day for 14 days); and Group C (n = 89), bismuth-containing quadruple regimen consisting of rabeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, and clarithromycin 500 mg (2 times/day for 14 days). Four weeks after treatment discontinuation, patients were examined for H. pylori infection by 13C-urea breath test. The rates of adverse effects, compliance, and eradication were evaluated.
resultsEradication rates in groups A, B, and C were 78.1, 81.6, and 84.3%, respectively, based on intention-to-treat analysis, or 79.1, 83.5, and 86.2%, according to per-protocol analysis. Rates of adverse events and compliance of the three groups were similar.
conclusionFor treating H. pylori infection, optimized high-dose amoxicillin-PPI dual therapies failed to achieve high cure rates in China and held no advantage over a bismuth-containing quadruple regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.